Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling

Circulation Research

Volumn 108, Issue 6, 2011, Pages 727-742

  Costandi, Justina ^a,b   Melone, Michelle ^a   Zhao, Alex ^b   Rashid, Shirya ^a,b  

^a HAMILTON GENERAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

apolipoprotein B; dyslipidemia; hepatic; obesity

Indexed keywords

APOLIPOPROTEIN B; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OLEIC ACID; PROTEIN KINASE B; RESISTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; FEMALE; HUMAN; HUMAN CELL; LIPID STORAGE; LIPOGENESIS; LIVER CELL; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN STABILITY; RAT; SIGNAL TRANSDUCTION;

ANIMALS; APOLIPOPROTEINS B; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; FATTY LIVER; HEP G2 CELLS; HEPATOCYTES; HUMANS; INSULIN; INSULIN RESISTANCE; INTRACELLULAR MEMBRANES; LIPID METABOLISM; LIPOPROTEINS, VLDL; LIVER; MICE; RATS; RESISTIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UP-REGULATION;

EID: 79953056591     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.238949     Document Type: Article

References (55)

1. Runge CF. Economic consequences of the obese. Diabetes. 2007;56: 2668-2672.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
3. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89:2595-2600. (Pubitemid 38766337)
4. Despres JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol. 2007;6:51-59.
5. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr, O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39-48. (Pubitemid 47016245)
6. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225-1236.
7. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol. 2006;17:238-246. (Pubitemid 43786057)
8. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170-176. (Pubitemid 32946865)
9. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology. 2007;132:2181-2190. (Pubitemid 46693753)
10. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma tri-glycerides in insulin resistance and diabetes. Arch Med Res. 2005;36: 232-240. (Pubitemid 40755136)
11. Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6:343-368.
12. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab. 2003;88:5452-5455. (Pubitemid 37452753)
13. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11:997-1001. (Pubitemid 41137512)
14. Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz WJ, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism. 2008;57:488-493. (Pubitemid 351317962)
15. Vozarova de Court, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes. 2004;53: 1279-1284. (Pubitemid 38569014)
16. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003;88:1730-1736. (Pubitemid 36623396)
17. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001; 98:502-506. (Pubitemid 32105071)
18. McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol. 2006;17:170-175.
19. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clin Sci (Lond). 2005;109: 243-256. (Pubitemid 41337128)
20. Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA. Mac-rophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest. 2009;119:531-539.
21. Sato N, Kobayashi K, Inoguchi T, Sonoda N, Imamura M, Sekiguchi N, Nakashima N, Nawata H. Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology. 2005;146:273-279. (Pubitemid 40051749)
22. Singhal NS, Patel RT, Qi Y, Lee YS, Ahima RS. Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice. Am J Physiol Endocrinol Metab. 2008;295:E331-E338.
23. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007;156:279-284. (Pubitemid 46554524)
24. Mason TM. The role of factors that regulate the synthesis and secretion of very-low-density lipoprotein by hepatocytes. Crit Rev Clin Lab Sci. 1998;35:461-487. (Pubitemid 29034227)
25. Olofsson SO, Bjursell G, Bostrom K, Carlsson P, Elovson J, Protter AA, Reuben MA, Bondjers G. Apolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process. Atherosclerosis. 1987;68:1-17.
26. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003; 14:281-287. (Pubitemid 36688207)
27. Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest. 2008;118:316-332.
28. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol. 1994;5:102-109. (Pubitemid 24116874)
29. Nordestgaard BG, Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol 1992;8:92-98.:92-8.
30. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 2010;33:1134-1139.
31. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212-1218. (Pubitemid 46684650)
32. Adeli K, Mohammadi A, Macri J. Regulation of apolipoprotein B biogenesis in human hepatocytes: posttranscriptional control mechanisms that determine the hepatic production of apolipoprotein B-containing lipoproteins. Clin Biochem. 1995;28:123-130.
33. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF, Adeli K. Mechanisms of hepatic very low density lipo-protein overproduction in insulin resistance. Evidence for enhanced lipo-protein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem. 2000;275:8416-8425. (Pubitemid 30180185)
34. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1-19. (Pubitemid 43776015)
35. Sheng CH, Di J, Jin Y, Zhang YC, Wu M, Sun Y, Zhang GZ. Resistin is expressed in human hepatocytes and induces insulin resistance. Endocrine. 2008;33:135-143.
36. Luo Z, Zhang Y, Li F, He J, Ding H, Yan L, Cheng H. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. Endocrine. 2009;36:60-69.
37. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr. 2007;86:353-359. (Pubitemid 47256918)
38. Lear SA, Birmingham CL, Chockalingam A, Humphries KH. Study design of the Multicultural Community Health Assessment Trial (M-CHAT): a comparison of body fat distribution in four distinct populations. Ethn Dis. 2006;16:96-100. (Pubitemid 46959252)
39. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 2004;1:e45.
40. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005; 111:932-939. (Pubitemid 40279897)
41. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733-749.
42. Carpentier A, Patterson BW, Leung N, Lewis GF. Sensitivity to acute insulin-mediated suppression of plasma free fatty acids is not a determinant of fasting VLDL triglyceride secretion in healthy humans. Diabetes. 2002;51:1867-1875. (Pubitemid 34564300)
43. Duez H, Lamarche B, Valero R, Pavlic M, Proctor S, Xiao C, Szeto L, Patterson BW, Lewis GF. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation. 2008;117:2369-2376. (Pubitemid 351653555)
44. Kim KH, Zhao L, Moon Y, Kang C, Sul HS. Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipo-genesis and improves insulin sensitivity. Proc Natl Acad Sci USA. 2004;101:6780-6785. (Pubitemid 38586051)
45. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem. 2001;276:11252-11256. (Pubitemid 38089312)
46. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229. (Pubitemid 34299024)
47. Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent down-regulation of c-Met. Nature. 2002;416:187-190. (Pubitemid 34246477)
48. Dashti N, Williams DL, Alaupovic P. Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. J Lipid Res. 1989;30:1365-1373. (Pubitemid 19253288)
49. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res. 1995;36:1073-1081.
50. Santamarina-Fojo S, Changting H, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1998;9: 212-219.
51. Beisiegel U. New aspects on the role of plasma lipases in lipoprotein catabolism and atherosclerosis. Atherosclerosis. 1996;124:1-8. (Pubitemid 26188202)
52. Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 1997; 17:2507-2514. (Pubitemid 28015987)
53. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem. 2009;42:1331-1346.
54. Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg. 2009;19:1313-1323.
55. Manduteanu I, Pirvulescu M, Gan AM, Stan D, Simion V, Dragomir E, Calin M, Manea A, Simionescu M. Similar effects of resistin and high glucose on P-selectin and fractalkine expression and monocyte adhesion in human en-dothelial cells. Biochem Biophys Res Commun. 2010;391:1443-1448.